Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients

Eleftherios Pelechas, Vassiliki Drossou, Paraskevi V. Voulgari, Alexandros A. Drosos

Mediterr J Rheumatol 2022;33(1):68-74
The pandemic of coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a matter of concern worldwide. Environmental factors such as smoking, obesity, cardio-respiratory diseases, diabetes mellitus and age may increase the severity of COVID-19. Current data demonstrated an acute dysregulation of the immune system during the severe form of the disease. The above is demonstrated by the clinical picture and laboratory findings, suggesting a severe inflammatory response of the innate immunity, affecting mainly the respiratory system with the recruitment in the lung parenchyma of macrophages, monocytes, and lymphocytes, followed by the thrombotic diathesis and multiorgan failure. Beside the clinical manifestations, the immune response is expressed with the activation of macrophages and lymphocytes generating a plethora of cytokines like interleukin (IL)-1, IL-6, IL-17, tumour necrosis factor alpha (TNFa) and chemokines, associated with increased serum ferritin levels and other acute phase reactants. On the other side, these cytokines play a pivotal role in autoimmune rheumatic diseases (ARD), mostly in rheumatoid arthritis (RA) and the spondyloarthopathies. Patients affected with ARD represent a particular vulnerable group, considering that they may be in an immunocompromised status due to their ailment and its treatment on one side, but on the other side, they may be protected from their immunosuppressive therapy. To this end, we present five patients with RA treated with conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) and biologic (b) DMARDs who were affected from COVID-19 and we will try to give answers to the above hypothesis.

The pandemic of coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a matter of concern worldwide. Environmental factors such as smoking, obesity, cardio-respiratory diseases, diabetes mellitus and age may increase the severity of COVID-19. Current data demonstrated an acute dysregulation of the immune system during the severe form of the disease. The above is demonstrated by the clinical picture and laboratory findings, suggesting a severe inflammatory response of the innate immunity, affecting mainly the respiratory system with the recruitment in the lung parenchyma of macrophages, monocytes, and lymphocytes, followed by the thrombotic diathesis and multiorgan failure. Beside the clinical manifestations, the immune response is expressed with the activation of macrophages and lymphocytes generating a plethora of cytokines like interleukin (IL)-1, IL-6, IL-17, tumour necrosis factor a (TNFa), and various chemokines. As a consequence, high levels of acute phase reactants are produced, such as C-reactive protein (CRP), hyperferritinæmia and hyper-fibrinogenæmia. Afterwards, a dysregulation of the adaptive immunity with reduction of lymphocytes mostly CD4+ and CD8+ T-cells takes place.
On the other hand, autoimmune rheumatic diseases (ARD) are also characterised by a dysregulation of the immune system in which several pro-inflammatory cytokines such as IL-1, IL-6, IL-17, and TNFα which are involved in the pathogenesis of rheumatoid arthritis (RA), the spondyloarthopathies (SpA), and inflammatory bowel disease (IBD). In the last two decades the introduction of biological (b) disease-modifying anti-rheumatic drugs (DMARDs) targeting cytokines, T and B cells, and with the use of conventional synthetic (cs) DMARDS, has revolutionized the treatment of the above diseases. The questions which arise here are: what is the impact of COVID-19 infection in patients with ARD “already treated with cs and bDMARDs”? Does their immunocompromised status due to the disease itself and its treatment put their life in danger? Are they protected against COVID-19 infection due to long use of cs and bDMARDs? For this reason, we present five patients with RA, treated with cs and bDMARDs, who were infected with COVID-19, and discuss the relevant literature trying to answer the above questions. An informed consent has been obtained from all patients.

**CASE PRESENTATION 1**
A 42-year-old woman was diagnosed 6 years earlier with RA on the basis of clinical and laboratory findings. More specifically, bilateral symmetrical polyarthritis of the small joints of the hands, positive anti-citrullinated protein antibodies (ACPA), positive IgM rheumatoid factor (IgM-RF), as well as high CRP and erythrocyte sedimentation rate (ESR). She was treated with hydroxychloroquine (HCQ) and methotrexate (MTX), plus 10mg of prednisone. She responded very well to the above treatment regimen since last year that developed a disease flare. Since then, adalimumab (ADA), an anti-TNFα inhibitor, was added. This treatment resulted in complete clinical and laboratory remission until recently. Indeed, on September 2, 2020 she experienced low-grade fever (37.7 °C), myalgias, arthralgias, and malaise. Clinical examination revealed no frank arthritis and the laboratory tests showed only a high CRP (14mg/dl - normal values <6) and high ESR (48mm/h). Chest x-ray was normal. Serological tests for viruses and bacteria, as well as blood and urine cultures were negative. However, the test for SARS-CoV-2 was positive. At that time, she was receiving HCQ (200mg/day), MTX (15mg/week), prednisone (2mg/day) and ADA (40mg/14 days subcutaneously) (sc). The last ADA injection was administered a week before the appearance of fever. She was not a smoker. Past medical and family history were unremarkable. We advised her to discontinue MTX and ADA, and to stay in isolation at home according to the national, European and American recommendations. Ten days later, her symptoms gradually subsided, and the symptoms resolved completely after 3 weeks. The repeated test for SARS-CoV-2 was negative. One month later, she was symptom-free, a new test for SARS-CoV-2 was also negative, and she started receiving her immunosuppressive therapy.

**CASE PRESENTATION 2**
A 50-year-old man was diagnosed as having RA 4 years ago, on the basis of symmetrical polyarthritis affecting the wrists, elbows and the knees bilaterally, and with positive IgM-RF and high ESR and CRP. He was treated with MTX 20mg/week, plus prednisone 10mg/day. He responded well, but a year later he relapsed, thus tocilizumab (TCZ), an IL-6 receptor antagonist was initiated (162mg/week sc). He responded very well to this treatment regimen, but on September 24, 2020, he complained of arthralgias, myalgias, sore throat, and fever up to 38°C. Clinical examination revealed no frank arthritis, chest x-ray was normal, and laboratory tests showed white blood count of 3.9/10^9/L with normal differential, high acute phase reactants and a SARS-CoV-2 test positive. The rest of the laboratory tests were negative or within normal limits. Past medical and family history were not significant. He was not a smoker. At this time, he was receiving MTX 15mg/week, prednisone 2.5 mg/day and TCZ 162mg/week. The last TCZ injection was administered three days before the initiation of his symptoms. MTX and TCZ were discontinued, and he stayed in isolation at home. A week later, he felt well, without sore throat and fever, and after 2 weeks, he had complete resolution of the SARS-CoV-2 symptoms. The repeated test for SARS-CoV-2 was negative and five weeks later a new test for SARS-CoV-2 was also negative so he started receiving the above-mentioned treatment (MTX and TCZ).

**CASE PRESENTATION 3**
A 62-year-old female with seronegative RA diagnosed 5 years earlier, was in clinical remission since 2018, receiving HCQ 200mg/day plus Etanercept (ETN) 50mg/week sc. She presented on 18th November 2020 with arthralgias, muscle aches, weakness, sore throat, altered sense of smell, and fever (38.5 °C). She visited our clinic, where after a detailed clinical and laboratory investigation, she was diagnosed as having SARS-CoV-2 infection. She had high ESR and CRP, as well as high ferritin levels (805mcg/L, normal values <35). She remained isolated at home receiving HCQ 200mg/day and azithromycin (AZT) 500mg/day, while ETN was discontinued. She was not receiving other drugs and she was not a smoker. Seven days later, she felt well without fever, sore throat and myalgias, but the olfactory dysfunction was still present. After three weeks she was free of symptoms. The patient started receiving ETN after a new SARS-CoV-2 negative test.

**CASE PRESENTATION 4**
A 55-year-old female with seropositive RA since 2016 receiving MTX 20mg/week and golimumab (GLM) 50mg/week was diagnosed as having RA 4 years ago, on the basis of serial positron emission tomography (PET) scans which revealed increased tracer uptake in the wrists, elbows and the knees bilaterally, and with positive IgM-RF and high ESR and CRP. She was treated with MTX 20mg/week which was discontinued after 3 weeks. The repeated test for SARS-CoV-2 was also negative. One month later, she was symptom-free, a new test for SARS-CoV-2 was also negative, and she started receiving her immunosuppressive therapy. ANTI-RHEUMATIC DRUGS IN COVID PATIENTS
month sc presented on 22nd November 2020 to us complaining of arthralgias, myalgias, sore throat, and loss of taste and smell. Clinical evaluation revealed no arthritis, while the laboratory tests showed high ESR and CRP, and positive SARS-CoV-2 test. She had no other co-morbidities and was not a smoker. She stayed at home receiving some analgesics, while MTX and GLM were discontinued. Two weeks later she felt better, but the loss of taste and smell had no improvement. After one month she was free of symptoms with some improvement of taste and smell. The SARS-CoV-2 test was negative, and she started receiving MTX and GLM.

**CASE PRESENTATION 5**

A 38-year-old female with a 12-year history of seronegative RA presented on 15th December 2020 with severe arthralgias and myalgias, as well as fever up to 38.5°C lasting for 3 days. She was on treatment with HCQ 200mg/day and prednisone 2.5mg/day because she delivered a healthy baby 6 months earlier. Past medical and family history were unremarkable. Clinical examination revealed no frank arthritis and she tested positive for SARS-CoV-2. The rest of the laboratory tests showed only high CRP. She continued receiving her drugs plus AZT 500mg/day and she stayed at home. After 10 days she felt better without fever, myalgias and arthralgias. One month later, the test for SARS-CoV-2 was negative.

**DISCUSSION**

In Table 1 we present the clinical and laboratory findings of those five RA patients who were infected with SARS-CoV-2. All infected patients presented systemic manifestations and mild upper respiratory symptoms from the nose and throat, while the laboratory investigation revealed only high acute phase reactants, mostly CRP and ESR, while one patient had also high ferritin levels. In addition, one patient had low white blood cells. None of these patients was hospitalized. Cs and bDMARDs were discontinued with the exception of HCQ and prednisone. The outcome of those patients was very good, lasting for 4-5 weeks until complete recovery.

Treatment decisions and therapeutic strategies in critically ill patients of SARS-CoV-2 infection were initially limited. Much of the therapy for severe Covid-19 are empirical and depend mostly on clinical judgement. However, up to date, different therapeutic protocols are applied using anti-viral drugs, steroids (mostly dexamethasone), supportive treatments, and several anti-rheumatic drugs, such as HCQ, cytokine inhibitors, and others. Regarding the patients with ARD infected from SARS-

Table 1. Clinical and laboratory findings of rheumatoid arthritis patients infected from SARS-CoV-2.

| Patients | Systemic manifestations | Ear, nose, and throat symptoms | Respiratory symptoms | Laboratory tests | Treatment | Outcome |
|----------|-------------------------|--------------------------------|----------------------|------------------|-----------|---------|
| N:1      | Arthralgias, myalgias, malaise, fever | None | None | High ESR High CRP | HCQ 200mg/day, prednisone 2.5mg | Good |
| N:2      | Arthralgias, myalgias, fever | Sore throat | None | High ESR High CRP Low WBC | Prednisone 2.5mg | Good |
| N:3      | Arthralgias, myalgia, weakness, fever | Sore throat, olfactory dysfunction | None | High ESR High CRP High Ferritin | HCQ 200mg/day AZT 500 mg/day | Good |
| N:4      | Arthralgias, myalgias | Sore throat, Loss of taste and smell | None | High ESR High CRP | None | Good |
| N:5      | Arthralgias, Myalgia, fever | None | None | High CRP | HCQ 200mg/day, prednisone 2.5mg/d, AZT 500mg/d | Good |

SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; WBC: white blood cells; HCQ: hydroxychloroquine; AZT: Azithromycin.
CoV-2, a study from Gianfrancesco et al. showed that patients receiving prednisone >10 mg/day had a higher probability to be hospitalised, while in those receiving anti-TNFα therapy, the risk of hospitalisation was low. Haberman et al. showed that antimalarial therapy was not associated with the likelihood of hospitalization in patients infected from SARS-CoV-2. On the other hand, bDMARDs and targeted synthetic (ts) DMARDs reduced the odds of hospitalization. In a subsequent study, the same investigators showed that among patients with ARDs and SARS-CoV-2 infection, the outcome was worse in those receiving corticosteroids, but none in those receiving anti-cytokine therapies. HCQ has been used in rheumatology for many years, especially for the treatment of RA and systemic lupus erythematosus (SLE). One question that arises at this point is, how could HCQ help patients suffering from SARS-CoV-2 infection. The answer is simple: we do not know yet, but what we do know is that HCQ inhibits or impairs the presentation process of an antigen, or of a microorganism to macrophages due to inhibition of toll-like receptors (TLRs). Another action of HCQ is that of helping macrophages to destroy the ‘invader’ in the cytoplasm through the action of lysosomes and blocks the major histocompatibility complex (MHC), which is responsible for the presentation of the ‘invader’ from macrophages to T cells. Therefore, T cell activation is inhibited (Figure 1). Could the above mechanisms of HCQ block the virus entry, and prevent its multiplication and spreading? We do not know, yet. However, in vitro studies showed that HCQ blocks viral replication by inhibiting the entry of SARS-CoV-2 by interacting with glycosylation of angiotensin converting enzyme-2 (ACE-2) receptor and its binding with the spike protein. This remains to be documented and there are some trials that are trying to support it. Furthermore, high HCQ blood levels are associated with reduced thrombotic events in SLE patients, which is also a clinical manifestation of SARS-

**Figure 1.** Antigen-processing onto macrophage/APC and the action of hydroxychloroquine. An antigen-presenting cell, takes up the pathogen (SARS-CoV-2) and engulfs it with phagocytosis (1). Lysosomes that contain acids create an acidic environment and fuse with the phagocytosed “invader” creating the phagolysosome which has an acidic environment too (2). Because of the acidic environment, the content of the phagolysosome breaks down leaving various particles that will be processed as antigens (3). In the meantime, within the endoplasmic reticulum the ribosomes are synthesizing MHC and allow the formation of an endosome which passes also through the Golgi apparatus to form a new endosome. The viral breakdown particles will then fuse with the new endosome and the particles will bind onto the groove of the MHC (4). Finally, the antigen presenting cell will express it on its self-surface (5). Hydroxychloroquine, accumulates in lysosomes, raising the pH establishing a non-acidic environment and inhibits the lysosomal activity and, in this way, it prevents the MHC presentation to the surface of the antigen-presenting cell.
CoV-2 patients. On the other hand, a study by Koning et al. found no protection for SARS-CoV-2 infection or the development of severe complication of the disease with the use of HCQ in patients with SLE.22 Recent data regarding the effect of HCQ in Covid-19 did not show a clear clinical benefit, while a systematic review and meta-analysis demonstrated that HCQ use was not associated with any benefit or harm regarding Covid-19 morbidity.24 IL-6, IL-1, and TNFα are the pivotal cytokines responsible for the clinical deterioration of patients suffering from SARS-CoV-2 infection. TCZ is an IL-6 receptor antagonist which is used in rheumatology for patients suffering from RA, juvenile idiopathic arthritis and temporal arthritis. There are several reports, using TCZ for critically ill patients infected with SARS-CoV-2, showing encouraging results.25,29 On March 3 2020, TCZ has been approved in China for use in patients with the SARS-CoV-2 infection. Indeed, TCZ maintains a crucial role in critically ill patients with acute progressive SARS-CoV-2. More than 200 cases of SARS-CoV-2 treated with TCZ have been published mostly from Chinese, Italian and Spanish investigators.31,32 In almost all cases, TCZ was found to be effective, with an acceptable safety profile. The clinical improvement has been associated with normalization of CRP and other acute phase reactants.30,28 In a few studies pulmonary improvement has been also noted by improvement of imaging findings.30 On the other hand, other studies, showed that high IL-6 was associated with severe phenotype disease of SARS-CoV-2.25 This is probably due to the fact that IL-6 levels may increase a few days after TCZ administration.33

Anakinra, is an IL-1 receptor antagonist which is used in RA, Still’s disease, cryopyrin-associated periodic syndrome (CAPS), and in patients with gout. Canakinumab, is a monoclonal antibody against IL-1 and it is used in CAPS and gout patients. Anakinra, showed reduction of CRP and progressive improvement of respiratory parameters in critically ill patients when administered intravenously and in high doses.24 Recently, Moutsopoulos HM described a patient suffering from CAPS who received Canakinumab 10 days before of being tested positive for SARS-CoV-2. He reported that the patient had a mild disease course and a week later the test for SARS-CoV-2 was negative.35 TNFα inhibitors are used in the last two decades for the treatment of RA, SpAs, and other inflammatory arthritis. It has been shown that the use of TNFα inhibitors in SARS-CoV-2 patients may improve disease outcome and prevent organ damage.36 The question that we addressed at the beginning, regarding the impact of SARS-CoV-2 infection in ARD patients, is still a matter of discussion due to limited data so far. However, single reports, as above, case series and observational studies published recently indicated that in patients with ARD and SARS-CoV-2 infection the disease is expressed with mild clinical symptoms without severe consequences probably due to their concomitant use of cs and bDMARDs.16-17,37-44 On the other hand, the Covid-19 Global Rheumatology Alliance (GRA) has published a series of papers dealing with the impact of COVID-19 in ARD patients.45 The results suggest that as in the general population, age and comorbidities are to blame as the risk factors for poor outcome in ARD patients infected by SARS-CoV-2. Furthermore, glucocorticoids are also associated with an unfavourable outcome in these patients. Finally, Stangfeld et al. who examined the casualties in a large amount of patients with ARDs, found that moderate or high disease activity, and specific drugs (sulfasalazine, azathioprine, cyclosporine-A, mycophenolate mofetil, tacrolimus, cyclophosphamide, and the use of rituximab) were associated with increased odds of COVID-19 deaths.46 However, all the above apply to a mixed population of ARD patients (SLE, scleroderma, RA and others) who may have many different systemic manifestations and treatments. The Janus-kinase (JAK) inhibitors tofacitinib (TOFA) and Baricitinib (BARI), have been proposed as potential therapeutic agents for SARS-CoV-2 infection. Especially BARI may block the viral entry into the cells by inhibiting the members of the numb-associated kinase (NAK) family, such as adaptor associated protein-kinase-1 (AAKI) and cyclin-G associated kinase (GAK), which are involved in the viral endocytosis.47 Currently, both drugs are used to treat RA and other inflammatory arthritides in a dose of 5mg twice daily for TOFA and 2mg twice daily for BARI. It has been shown that BARI is able to inhibit effectively AAKI and GAK with the above approved dose for RA. Moreover, BARI as a selective inhibitor of JAK 1 and 2 and TOFA as an inhibitor of JAK1 and 3 are also able to inhibit the inflammatory response of SARS-CoV-2, especially IL-1 and INF-γ. Several studies indicated that JAK inhibitors may have some beneficial effect in the treatment of COVID-19.19,48-50 However, recent studies evaluating the impact of the COVID-19 on morbidity and mortality in patients with ARDs indicated that the use of JAK inhibitors had a negative effect.50,51 In the present report we present five patients with RA in clinical remission without systemic manifestations and comorbidities who were treated with cs and bDMARDs that achieved a good outcome. Indeed, our RA patients during the SARS-CoV-2 infection were receiving csDMARDs (HCQ and MTX), while three of them were receiving also TNFα inhibitors, and one patient was on treatment with an IL-6 receptor antagonist. All had mild clinical manifestations and very good outcome with complete resolution of their symptoms, without hospitalisation and no additional therapy. Another factor which may have influenced the clinical manifestations of our patients is that none of them had other comorbidities, like diabetes mellitus, coronary disease, hypertension, and other diseases which may play crucial role in the deterioration
of the clinical course and outcome of SARS-CoV-2. All patients, except one, restarted their immunosuppressive therapy for RA after a negative test for Covid-19, which is in line with the international guidelines. Alternatively, the immunosuppressive therapy should be restarted after a two-week, symptom free period of the patient. Thus, we can hypothesise that anti-rheumatic drugs may ameliorate the clinical picture and disease course of COVID-19 in RA patients. However, further studies with a large number of patients are needed in order to confirm the above beneficial effects of the anti-rheumatic drugs.

ACKNOWLEDGEMENT
The authors would like to especially thank Ms Areti Fili for her excellent secretarial support.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Zhou F, Y T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62.
2. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395(10228):e52.
3. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-8.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4.
5. Davison A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345(3):340-50.
6. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2015;11:88.
7. Burmester GR, Feist E, Donner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88.
8. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020;39(7):2055-62.
9. Recommendations regarding COVID 19 infection in Rheumatic patients in Greece – The Greek Rheumatology Society and Professional Association of Rheumatologists – ERE-EPERE. Medit J Rheumatol 2020;31(1):6-7.
10. European League against Rheumatism. EULAR.org/eular_guidance_for_patients_covid19_outbreak.cfm. Accessed on 05 January 2020.
11. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, et al. COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72(12):1981-9.
12. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 2020;72(12):1981-9.
13. Harberman R, Axlrad J. Covid-19 in immune-mediated inflammatory diseases. Case series from New York. N Engl J Med 2020;NEJMc2009672.
14. Harberman RH, Castillo R, Chn A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 2020;72(12):1981-9.
15. Gaurtred P, Lagier JC, Parola P, Hoang VT, Meddeb L, Malhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
16. Yao X, Ye F, Zhang M, Cui C, Huang B, Ni P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;ciaa237.
17. Virdis A, Tani C, Duranti E, Vagnani S, Carli L, Kuhl AA, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Rheum Ther 2015;17:277.
18. Xue H, Liu Y, Luo P, Liu X, Qiu L, Du D, et al. Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China. J Med Virol 2020;92:2523-7.
19. Petri M, Konig MF, Li J, Goldman DW. Higher hydroxychloroquine blood levels are associated with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol 2021;73:997-1004.
20. Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID. Ann Rheum Dis 2020;79(10):1386-8.
21. Putman M, Chock YPE, Tam H, Kim AH-U, Sattai E, Berenbaum F, et al. Antirheumatic Disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 2021;73(1):36-47.
22. Fu B, Xu X, Wei H, Wu J, Li X, Wu J, et al. Early tocilizumab treatment could improve survival among COVID-19 patients with severe COVID-19. J Med Virol 2020;92(7):814-8.
23. Giambenedetto S, Cicuollo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol 2020;92(10):1787-8.
24. Piva S, Filippini M, Turfa F, Cattaneo S, Margola A, de Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 2020;58:29-33.
25. Cellina M, Orsi M, Bornbaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after tocilizumab treatment. J Med Virol 2020;92(10):1787-8.
26. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814-8.
27. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117(20):10970-5.
28. Visconti E, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol 2020;92(10):1787-8.
29. Putman M, Chock YPE, Tam H, Kim AH-U, Sattai E, Berenbaum F, et al. Antirheumatic Disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 2021;73(1):36-47.
30. Fu B, Xu X, Wei H, Wu J, Li X, Wu J, et al. Early tocilizumab treatment could improve survival among COVID-19 patients with severe COVID-19. J Med Virol 2020;92(7):814-8.
31. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, et al. COVID-19 global rheumatology alliance physician-reported registry for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020;79(7):859-66.
32. Bernstein RH, Castillo R, Chn A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 2020;72(12):1981-9.
33. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T, et al. Mechanisms and pathologic significances in increase in serum in-
terleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112(10):3959-64.

34. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2(6):e325-e331.

35. Moutsopoulos HM. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis 2020 Sep;79(9):1253-4.

36. Roux CH, Brocq O, Gerald F, Pradier C, Baily L. Clinical impact of COVID-19 on a French population of spondyloarthritides patients. Clin Rheumatol 2020;39(11):3185-3187. Doi: 10.1007/s10067-020-05413-9.

37. Mihai C, Dobrota R, Schroder M, Garaian A, Jordan S, Becker MO. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSC-ILD, Ann Rheum Dis 2020;79:668-9.

38. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020;79(6):837-9.

39. Han Y, Jiang M, Xia D, He L, Lv X, Liao X, et al. COVID-19 in a patient with long-term use of glucocorticoids. A study of a familial cluster. Clin Immunol 2020;214:108413.

40. Roux CH, Brocq O, Gerald F, Pradier C, Baily L. Clinical impact of COVID-19 on a French population of spondyloarthritides patients. Clin Rheumatol 2020;39(11):3185-3187. Doi: 10.1007/s10067-020-05413-9.

41. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 2021;80(9):1137-46.

42. Mikulis TR, Johnson SR, Raeser O, Arasarathnam RJ, Baden LR, Bemias BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72(8):1241-51.

43. Barlow-Pay F, Hutt TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Sci Saf 2021;12:2042086202098587.